{"id":"W4386447675","doi":"10.1200/jco.22.02906","title":"Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":71,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"Daiichi Sankyo Europe; EMD Serono; Genentech; PharmaMar; Swedish Orphan Biovitrum; Eisai; G1 Therapeutics; MacroGenics; AstraZeneca España; Amgen; Radius Health; Syndax Pharmaceuticals; BeiGene; Clovis Oncology; Pfizer; Incyte; NuCana; AstraZeneca; Novocure; Ipsen; Jazz Pharmaceuticals; Taiho Pharmaceutical; Mersana Therapeutics; Exelixis; Karyopharm Therapeutics; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Sanofi; GlaxoSmithKline; Plexxikon; Seagen; Relay Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Endometrial cancer; Chemotherapy; Oncology; Maintenance therapy; Internal medicine; Gynecologic cancer; Cancer; Gynecology; Ovarian cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001305247,0.0001457604,0.0006261757,0.00007893003,0.00004407106,0.0000100954,0.0001908151,0.000369895,0.0002222563],"category_scores_gemma":[0.002205081,0.00009151606,0.0004577919,0.0001884493,0.00008629478,0.000008680842,0.00003464447,0.0002869291,0.0000118985],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003436776,"about_ca_system_score_gemma":0.0005218044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004420312,"about_ca_topic_score_gemma":0.0001245417,"domain_scores_codex":[0.9981682,0.0001209887,0.001061471,0.0002425557,0.0001543947,0.0002523549],"domain_scores_gemma":[0.9981412,0.0003969218,0.0007588663,0.0001653877,0.0003921111,0.0001454941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1024196,0.0002824427,0.001758255,0.00001329592,0.0002859325,0.00003563781,0.0000293747,0.00009841654,0.006191782,0.00001342339,0.04111553,0.8477563],"study_design_scores_gemma":[0.0151719,0.02045132,0.007614098,0.0000234149,0.00004018419,0.00003697638,0.00002401617,0.0000649039,0.002241241,0.0003661481,0.953836,0.0001297599],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835249,0.00107953,0.0009775589,0.007501193,0.006407587,0.0003654768,0.0000261469,0.00001157382,0.0001060126],"genre_scores_gemma":[0.9321606,0.04282309,0.004781336,0.007724846,0.009831439,0.0000778258,0.00002597901,0.00005925192,0.002515628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9127205,"threshold_uncertainty_score":0.3731917,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08886164544139567,"score_gpt":0.4607676338415168,"score_spread":0.3719059884001211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}